Business Boehringer to release an obesity, fatty liver drug by 2027 or 2028By Gazet InternationalFebruary 27, 20240 Boehringer Ingelheim, a German drugmaker, expressed its aspiration to launch survodutide, a drug candidate co-developed with Zealand Pharma (ZELA.CO), with the potential to treat obesity and… Read More
